EXELIXIS, INC.
Financial highlights
| Metric | FY 01/02/26 | FY 01/03/25 | FY 12/29/23 | FY 12/30/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B |
| Cost of revenue | $83.7M | $76.2M | $72.5M | $57.9M | $52.9M |
| Selling, general & administrative | $518.7M | $492.1M | $542.7M | $459.9M | $401.7M |
| Research and development | $825.0M | $910.4M | $1.0B | $891.8M | $693.7M |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Income tax expense | $158.6M | $160.4M | $49.8M | $52.1M | $63.1M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| Balance Sheet | |||||
| Cash and equivalents | $482.5M | $217.4M | $263.0M | $501.2M | $647.2M |
| Current assets | $1.4B | $1.5B | $1.3B | $1.6B | $1.8B |
| Total assets | $2.8B | $2.9B | $2.9B | $3.1B | $2.6B |
| Current liabilities | $405.6M | $403.8M | $394.3M | $324.4M | $337.6M |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M | $405.6M |
| Stockholders' equity | $2.2B | $2.2B | $2.3B | $2.5B | $2.2B |
| Cash Flow Statement | |||||
| Cash from operations | $884.3M | $700.0M | $333.3M | $362.6M | $400.8M |
| Depreciation and amortization | $29.1M | $28.8M | $25.7M | $20.9M | $13.6M |
| Stock-based compensation | $113.0M | $93.8M | $106.3M | $107.6M | $119.8M |
| Capital expenditure | $8.4M | $28.4M | $40.5M | $27.7M | $54.2M |
| Free cash flow | $875.8M | $671.5M | $292.9M | $334.9M | $346.6M |
| Share repurchases | $947.5M | $652.0M | $550.4M | $0 | $0 |
| Impairments | $0 | $64.4M | $0 | $0 | $0 |
Shares outstanding 251.4M · Free float 96.8%
Annual filing data through FY ended January 2, 2026; float as of July 11, 2026.